AOD-9604 for Weight Loss

The short answer on AOD-9604 and weight loss

Most peptides marketed for fat loss were never tested as weight-loss drugs at all — they were studied for something else and repurposed by the wellness market. AOD-9604 is the rare exception. It was designed from the start to be an anti-obesity medicine, taken into a real human trial program for exactly that purpose, and measured against the only outcome that matters for a weight-loss drug: pounds lost on the scale versus placebo.

That makes its story unusually clean to summarize. The early human signal was small. The larger, more definitive trial did not hold up. Development was stopped. If you are weighing AOD-9604 as a weight-loss option in 2026, the most useful thing to know is that the medicine was given its fair test for this exact use — and the test came back negative.

This page focuses on that clinical weight record: the trials, the numbers on the scale, and what they mean. The cellular fat-burning rationale (lipolysis and body-composition claims) is a different argument with its own page, and the practical questions of cost and legal access each have their own as well. Here, we stay on the question people actually type: does it take weight off?

What AOD-9604 was built to do

AOD-9604 is a short synthetic peptide based on the tail end of the human growth hormone molecule. Growth hormone has a known fat-metabolizing effect, but it also drives blood-sugar problems, fluid retention, and tissue growth. The idea behind AOD-9604 was to isolate just the fat-handling portion and leave the rest behind — fat-burning without the baggage. That premise is genuinely appealing on paper, and it is why the molecule drew investment in the first place. (For the full background on what the molecule is and how it differs from growth hormone, see the dedicated explainer.)

The crucial design choice for understanding the weight-loss claim is this: because AOD-9604 was meant to act on fat metabolism rather than on appetite, it was never expected to make people eat less. Modern weight-loss medicines work largely by reducing how much you want to eat. AOD-9604 was deliberately built to do something different, which shapes — and limits — what kind of scale result it could ever plausibly produce.

The clinical trial record

This is the heart of the matter, so it is worth being precise.

In the 2000s, the Australian company Metabolic Pharmaceuticals ran AOD-9604 through a structured obesity program in humans. Across the full program, the compound was studied in several randomized, double-blind, placebo-controlled trials involving well over 900 participants. Notably, the studied form was an oral tablet taken once daily across a set of low-milligram dose groups — not the injectable vials sold on today’s gray market. That distinction matters and we return to it below.

The early signal. An earlier-phase study over roughly 12 weeks produced the result you still see quoted everywhere: participants on the active compound lost around 2.6 kg, versus about 0.8 kg on placebo. Strip out the placebo effect and the true drug-attributable advantage was under 2 kg over three months. The trial was small — only around two dozen people per dose arm — so it functioned as a proof of concept, not proof of clinical benefit. The safety profile looked reassuring, with no growth-hormone-style side effects, no IGF-1 elevation, and no glucose problems. That clean safety record is real, and it is part of why the compound still gets a sympathetic hearing.

The pivotal trial. Metabolic then ran the larger, decisive study — the Phase 2b OPTIONS trial — in more than 500 obese adults over 24 weeks, testing multiple doses against placebo. The primary endpoint was mean weight change from baseline. The headline result: AOD-9604 did not separate from placebo on weight at any dose tested. The small early signal did not reproduce in the bigger, longer, better-powered study.

The aftermath. Following that failure, Metabolic Pharmaceuticals discontinued AOD-9604’s development as an obesity drug around 2007. It never advanced to Phase 3, and it has never been approved as a weight-loss medicine in the United States or anywhere else. A telling footnote: the detailed Phase 2b results were not published in a peer-reviewed journal. In drug development, a pivotal trial that goes unpublished is itself a quiet signal about how the data looked.

Note: Two numbers get mixed up online. The flattering “2.6 kg” figure comes from the small early study; the trial that was supposed to confirm it — the large one — is the trial that failed. When a vendor cites the encouraging number without mentioning the pivotal failure, that selective framing is the tell.

Why the mechanism caps what the scale can show

The trial outcome makes more sense once you look at the mechanism. Because AOD-9604 was engineered to nudge fat metabolism rather than suppress appetite, it has no lever on the single biggest driver of weight loss in real life: how much a person eats. A compound that does not change intake and does not change IGF-1-driven body composition has a narrow path to moving the scale, and the human data reflect exactly that narrow path.

The deeper argument about whether AOD-9604 meaningfully stimulates fat breakdown at the cellular level — the lipolysis case, the animal data, the body-composition versus scale-weight distinction — is a separate discussion covered on its own page. The point for weight loss specifically is simpler: whatever the biology suggests in a dish or a mouse, the human weight outcome was tested directly and came back essentially flat.

How that compares to today’s weight-loss medicines

The most honest way to size up AOD-9604 is against the drugs that actually clear the bar it failed. Approved GLP-1 and dual GLP-1/GIP medicines — semaglutide and tirzepatide — have produced average body-weight reductions in roughly the mid-teens to low-twenties percent range in large, published, peer-reviewed trials, with clear separation from placebo. For a person who weighs 100 kg, that is on the order of 15 to 22 kg.

Set that beside AOD-9604’s best-case figure of a couple of kilograms over placebo in a small study that the definitive trial then contradicted, and the gap is not subtle — it is roughly an order of magnitude, before you even account for the pivotal failure. This is the single most useful comparison for anyone choosing a weight-loss route in 2026: one option has a large, replicated, published evidence base behind a regulated supply chain; the other ran the same gauntlet and washed out.

What “results” people report versus what trials found

Plenty of online reviews and transformation photos claim weight loss on AOD-9604, and that apparent contradiction with the trial data deserves a plain explanation. Anecdotal results are almost always confounded: people start AOD-9604 alongside a new diet, harder training, a calorie deficit, or other compounds — and any weight lost gets attributed to the peptide. Controlled trials exist precisely to subtract those confounders, and when they did, the weight advantage largely disappeared. The week-by-week pattern people describe, the subjective user reports, and the before-and-after photo genre each have their own page; the short version is that none of them override a placebo-controlled trial that measured the same thing and found no separation.

US legal status in 2026, in brief

A quick orientation, since legality shapes whether any of this is academic. The 2026 regulatory picture for compounded peptides is in motion but not finalized. In April 2026 the FDA removed a cohort of 12 peptides from its restrictive Category 2 list and scheduled advisory-committee review of several of them for possible future compounding — a process that is still pending, with no peptide yet placed on the authorized 503A bulks list through it.

AOD-9604 is not part of that active cohort. Its compounding question was examined earlier and not advanced, which leaves it outside the lawful 503A compounding pathway rather than waiting in line for it. A prescription can be written, but a licensed pharmacy generally cannot lawfully fill it. The mechanics of that — and what the gray-market and research-only routes actually involve — are covered in depth on the access and regulatory pages; treat anything you read here as current as of this page’s date and subject to change.

What to ask a provider — and the honest alternative

If you are still considering AOD-9604 for weight loss, the most valuable questions to put to any clinic are about evidence and legitimacy, not about how to obtain it. Ask: what published human weight-loss trial supports this for me specifically? Why was the obesity program discontinued? Is the product something a licensed US pharmacy can lawfully dispense, or is it research-only material of unverified content? A provider who answers “we can get it, no problem” without engaging those questions is a red flag, not a green light. Watch, too, for the false claim that AOD-9604 became “legal again” in the 2026 reclassification — it was not part of that change.

And there is a fair, direct alternative worth naming. If your real goal is weight loss rather than this particular molecule, the route with both a strong evidence base and a lawful supply chain is the approved GLP-1 class. Those medicines did, repeatedly and in published trials, what AOD-9604 was asked to do and could not. The practical steps for accessing them legitimately are covered on the relevant guides.

The bottom line on AOD-9604 for weight loss is the same one its own clinical program reached nearly twenty years ago: tested fairly for this exact purpose, it did not deliver — and nothing in the years since has changed that verdict.